Sugi Predict

Sugi Predict / Compounds / SCHEMBL19914979

SCHEMBL19914979

SCHEMBL19914979

C[C@H]([C@H](C)c1cccc(F)c1)[C@H]1CCCN1C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ RIPK1 Q13546 1/20 0.47
▸ GPR119 Q8TDV5 1/20 0.43
▸ DPP4 P27487 1/20 0.42
▸ DPP7 Q9UHL4 1/20 0.42
▸ NR1H3 Q13133 4/20 0.42
▸ NR1H2 P55055 3/20 0.42
▸ UCHL1 P09936 1/20 0.41
▸ LMNA P02545 3/20 0.40
▸ TSHR P16473 2/20 0.40
▸ NPSR1 Q6W5P4 1/20 0.40
▸ GHSR Q92847 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ KMT2A Q03164 1/20 0.40
▸ NTRK1 P04629 1/20 0.40
▸ NPC1 O15118 1/20 0.39
▸ ALDH1A1 P00352 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19914962 0.92 RIPK1 (0.46) RIPK1GPR119DPP4DPP7NR1H3
SCHEMBL19914975 0.90 RIPK1 (0.44) RIPK1GPR119DPP4DPP7NR1H3
SCHEMBL31012172 0.88 RIPK1 (0.48) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL31012174 0.88 RIPK1 (0.48) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL10132260 0.88 RIPK1 (0.48) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL3442875 0.85 RIPK1 (0.45) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL19915020 0.84 RIPK1 (0.40) RIPK1GPR119DPP4DPP7NR1H3
SCHEMBL19897264 0.83 RIPK1 (0.44) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL19897265 0.83 RIPK1 (0.44) RIPK1GPR119NR1H3NR1H2UCHL1
SCHEMBL19897307 0.83 RIPK1 (0.44) RIPK1GPR119NR1H3NR1H2UCHL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11912715-B2 Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections NOVARTIS AG (CH) 2024-02-27 — — US disclosed
US-20230322793-A1 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza NOVARTIS AG (CH) 2023-10-12 — — US disclosed
US-20180057501-A1 FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, INC. 2018-03-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180057501-A1 FUSED TRICYCLIC PYRIDAZINONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS ZC3HAV1, ZC3HAV1L, CUL5 RIPK1 2665/4885GPR119 2883/4885DPP4 106/4885
US-11912715-B2 Fused tricyclic pyridazinone compounds useful to treat orthomyxovirus infections ZC3HAV1, ZC3HAV1L, CUL5 RIPK1 2665/4885GPR119 2883/4885DPP4 106/4885
US-20230322793-A1 10-(di(phenyl)methyl)-4-hydroxy-8,9,9A,10-tetrahydro-7H-pyrrolo[1 ',2':4,5]pyrazino[1,2-B]pyridazine-3,5-dione Derivatives and Related Compounds as Inhibitors of the Orthomyxovirus Replication for Treating Influenza MAVS, ZC3HAV1, EIF2AK2 RIPK1 2664/4885GPR119 2032/4885DPP4 102/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.